Oral bisphosphonate alendronate does noot reduce the incidence of fractures in children with osteogenesis imperfecta. This has been suggested by findings findings published November 24th online in The Journal of Clinical Endocrinology & Metabolism.
With an objective to study the efficacy and safety of daily oral alendronate in children with osteogenesis imperfecta, Dr Ward et al conducted a multicenter, double-blind, randomized, placebo-controlled study.
The study included 139 children between 4–19 years of age having with type I, III, or IV osteogenesis imperfecta. [Read more...]


Join Discussions